Takeda reported head-to-head Phase 3 results for its AI-designed oral psoriasis drug zasocitinib, claiming complete skin clearance in more than 35% of patients at 16 weeks. The company said the outcome exceeded Bristol Myers Squibb’s Sotyktu (deucravacitinib) by more than 2.5x in the same timeframe. Takeda positioned the response as both faster and more durable, with separation from control apparent as early as week 8, and also cited improvements in secondary measures including PASI 90. The program targets the TYK2 protein with sustained IL-23 inhibition over 24 hours. The data strengthen Takeda’s regulatory path, with the company signaling an FDA submission “in the coming months.” Takeda acquired zasocitinib from Nimbus Therapeutics for $4 billion in December, underscoring the scale of its bet on oral TYK2 inhibition for inflammatory disease.